Clinical and Biochemistry Determinants for Bnp and Renin-Angiotensin-Aldosterone Activation in Patients With Heart Failure
Michael White, Simon de Denus(Montreal Heart Institute), Marie‐Pierre Dubé(Montreal Heart Institute), Julie L. Lavoie, Eileen O’Meara(Montreal Heart Institute), Normand Racine(Montreal Heart Institute), Simon Kouz, Abdelsalam M. Mansour, M.-R. Guertin, J.‐C. Tardif, Jean L. Rouleau(Montreal Heart Institute), M Leblanc, Serge Lepage, R. C. Sheppard(Northside Hospital), Anique Ducharme(Montreal Heart Institute)
Cited by 0
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure
|New England Journal of Medicine|2010|1.8k
Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure
|New England Journal of Medicine|2008|1.6k
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial
|Circulation|2014|1k
Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
|Nature Genetics|2003|976